

May 26<sup>th</sup>, 2014

VRL/SEC/BSE

**Dept. of Corporate Services  
The Stock Exchange, Mumbai  
25<sup>th</sup> Floor, Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai**

**Sub. : Venus Remedies bags additional patent for Vancoplus from US**

Dear Sir/Madam,

This is to inform you that Venus Remedies Limited has bagged additional patent for Vancoplus from USPTO. Vancoplus is an antibiotic adjuvant entity effective in one the most deadly resistance by Methicillin Resistant *Staphylococcus Aureus* (MRSA). Developed by the Venus Medicine Research Centre (VMRC), the R&D wing of Venus Remedies, Vancoplus is the only solution till date for MRSA with more than 9 per cent of success rate.

The patent is valid till 2032. The company has already initiated process for pre IND meeting with US FDA and is quite optimistic to get fast track approval for this product because MRSA is under the list of limited pathogens identified under GAIN act by FDA and Vancoplus falls in that QIDP category.

Venus Remedies already have product patent for Vancoplus from US PTO, this additional patent with broader coverage for use and method of treatment will be beneficial for the company. The formulation will be commercialized in the US market through technology transfer/outlicensing of exclusive marketing rights route and we are open for such deals.

Vancoplus a novel antibiotic adjuvant entity highly effective against MRSA, VISA, hGISA and mixed bacterial infections of gram negative & gram positive pathogens. Vancoplus is the best and safest option to address such infections. It is also active against different mechanisms of resistance such as Cell Membrane impermeability, Efflux pumps, Biofilms, which no other therapeutic options available are able to address.

It took the VMRC more than seven years to develop this product, which has received an overwhelming response from the medical fraternity in India since it was launched in the country four years ago and the product is growing with more than 25% CAGR in Indian market.

## **VENUS REMEDIES LIMITED**

Corporate Office :

51-52, Industrial Area, Phase-I,  
Panchkula (Hry.) 134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India

Website : [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272

Unit-V :

VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany

In USA alone, MRSA is associated with a staggering 90,000 infections and an estimated 19,000 deaths annually. Global Antibacterials Market which is slated to reach approx US \$64 bn by the year 2018 with a growth rate of 7.5%. Vancoplus is segmented in Hospital Treated Infection Market which is growing at a rate of 2.7%. By taking sales of competitors brands in 2013 as addressable market for Vancoplus, which stands at US \$Mn 2610.

In view of the steep rise in the prevalence of MRSA, VRSA and hGISA infections, Vancoplus will be the need of the hour, due to its high potency against these infections and mixed bacterial infection of gram negative & gram positive pathogens. Venus has developed Vancoplus to address this unmet need.

Besides this, Venus has also secured US patent for its novel research products ELORES, Potentox and Achnil.

Yours faithfully,  
for VENUS REMEDIES LIMITED.


*Ramanjit*

Ramanjit Kaur  
Deputy Manager  
Corporate Communication



## VENUS REMEDIES LIMITED

Corporate Office :  
51-52, Industrial Area, Phase-I,  
Panchkula (Hry.) 134113, India  
Regd. Office :  
SCO 857, Cabin No. 10, 2nd Floor, NAC,  
Manimajra, Chandigarh (U.T.) 160101, India  
Website : [www.venusremedies.com](http://www.venusremedies.com)  
[www.venusmedicineresearchcentre.com](http://www.venusmedicineresearchcentre.com)



Unit-I :  
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566  
Unit-II :  
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),  
Bhatoli Kalan, Baddi (H.P.) 173205, India  
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272  
Unit-V :  
VENUS PHARMA GmbH  
AM Bahnhof 1-3, D-59368, Werne, Germany